PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1635119
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1635119
Next-Generation Antibody Therapeutics Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)
The global next-generation antibody therapeutics market is projected to grow from $2,686.2 million in 2024 to $4,139.1 million by 2030, reflecting a compound annual growth rate (CAGR) of 7.6% during the forecast period.
This growth is driven by advancements in monoclonal antibody technology, which offer high safety and efficacy, and increasing investments in the healthcare sector. The rising prevalence of chronic diseases, such as autoimmune disorders and cancer, necessitates the development of innovative therapeutics, further propelling market expansion.
Key Insights
The oncology therapeutic area accounts for the largest revenue share, approximately 90% in 2024, and is expected to showcase the highest CAGR, around 8%, during the forecast period. This is due to the increasing incidence of various cancers and the effectiveness of antibody therapeutics in targeting cancer cells while minimizing damage to healthy tissues.
Antibody-drug conjugates (ADCs) are gaining traction as they combine the targeting capabilities of antibodies with the cytotoxic potential of chemotherapy drugs, enhancing treatment efficacy and specificity. Pharmaceutical and biotechnology companies are increasingly focusing on developing ADC-based therapeutics, particularly for cancer treatment.
North America leads the market, attributed to significant investments in R&D, a strong presence of major pharmaceutical companies, and a high prevalence of chronic diseases. The region's advanced healthcare infrastructure and supportive regulatory environment further contribute to market dominance.
The Asia-Pacific region is anticipated to experience the fastest growth during the forecast period, driven by increasing healthcare expenditures, rising awareness of advanced therapeutics, and a growing patient population. Government initiatives to improve healthcare infrastructure and support biopharmaceutical research also play a crucial role.
The market is consolidated, with major players such as F. Hoffmann-La Roche, AstraZeneca plc, and ImmunoGen Inc. leading the development of cutting-edge ADCs and monoclonal antibodies targeting oncological and autoimmune diseases. Collaborations and partnerships among pharmaceutical companies, biotech firms, and research institutions are common, fostering innovation and expanding product pipelines.
High production costs pose challenges to market growth, as complex manufacturing procedures, advanced technology, and prolonged clinical trials are required to bring novel treatments to market. Efforts to streamline production processes and reduce costs are ongoing to make these therapies more accessible.
International partnerships and funding, such as those from the Global Health Innovative Technology Fund and Cancer Research UK, support R&D for next-generation antibodies, facilitating the development of innovative therapeutics and expanding market opportunities.
The increasing focus on personalized medicine is driving the development of next-generation antibody therapeutics tailored to individual patient profiles, enhancing treatment efficacy and minimizing side effects. This trend is expected to create new opportunities and shape future market dynamics.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by therapeutic area
- 1.4.2. Market size breakdown, by technology
- 1.4.3. Market size breakdown, by region
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Therapeutic Area (2019-2030)
- 6.3. Market Revenue, by Technology (2019-2030)
- 6.4. Market Revenue, by Region (2019-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Therapeutic Area (2019-2030)
- 7.3. Market Revenue, by Technology (2019-2030)
- 7.4. Market Revenue, by Country (2019-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Therapeutic Area (2019-2030)
- 8.3. Market Revenue, by Technology (2019-2030)
- 8.4. Market Revenue, by Country (2019-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Therapeutic Area (2019-2030)
- 9.3. Market Revenue, by Technology (2019-2030)
- 9.4. Market Revenue, by Country (2019-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Therapeutic Area (2019-2030)
- 10.3. Market Revenue, by Technology (2019-2030)
- 10.4. Market Revenue, by Country (2019-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Therapeutic Area (2019-2030)
- 11.3. Market Revenue, by Technology (2019-2030)
- 11.4. Market Revenue, by Country (2019-2030)
Chapter 12. Competitive Landscape
- 12.1. List of Market Players and their Offerings
- 12.2. Competitive Benchmarking of Key Players
- 12.3. Product Benchmarking of Key Players
- 12.4. Recent Strategic Developments
Chapter 13. Company Profiles
- 13.1. F. Hoffmann-La Roche Ltd.
- 13.1.1. Business overview
- 13.1.2. Product and service offerings
- 13.1.3. Key financial summary
- 13.2. Kyowa Kirin Co. Ltd.
- 13.2.1. Business overview
- 13.2.2. Product and service offerings
- 13.2.3. Key financial summary
- 13.3. AbbVie Inc.
- 13.3.1. Business overview
- 13.3.2. Product and service offerings
- 13.3.3. Key financial summary
- 13.4. Takeda Pharmaceutical Company Limited
- 13.4.1. Business overview
- 13.4.2. Product and service offerings
- 13.4.3. Key financial summary
- 13.5. Amgen Inc.
- 13.5.1. Business overview
- 13.5.2. Product and service offerings
- 13.5.3. Key financial summary
- 13.6. Pfizer Inc.
- 13.6.1. Business overview
- 13.6.2. Product and service offerings
- 13.6.3. Key financial summary
- 13.7. Catalent Inc.
- 13.7.1. Business overview
- 13.7.2. Product and service offerings
- 13.7.3. Key financial summary
- 13.8. AstraZeneca plc
- 13.8.1. Business overview
- 13.8.2. Product and service offerings
- 13.8.3. Key financial summary
- 13.9. Xencor Inc.
- 13.9.1. Business overview
- 13.9.2. Product and service offerings
- 13.9.3. Key financial summary
Chapter 14. Appendix
- 14.1. Abbreviations
- 14.2. Sources and References
- 14.3. Related Reports
